Clinical Research Directory

Inclusion Criteria: * Active patient aged between 18 and 65; * Patient suffering from pain compatible with supraspinatus tendinopathy for at least 2 months; * Patient with simple tendinopathy or partial tendon rupture; * Patient with tendinopathy confirmed by ultrasound or MRI; * Patient with an active pain visual analog scale ≥ 4 for more than 6 weeks; * Patient with an active pain visual analog scale ≥ 4 on the day of inclusion; * Patient failing medical treatment (rest, analgesics, NSAIDs, physiotherapy); * Patient able to follow the protocol and having given oral informed consent to take part in the research; * Patient affiliated to the social security system or entitled person; Exclusion Criteria: * Patient suffering from a transfixing tendon rupture; * Patients suffering from post-traumatic tendon rupture; * Patients suffering from calcific tendinopathy (calcification \> 5 mm); * Patients with associated glenohumeral osteoarthritis; * Patients with associated symptomatic acromioclavicular osteoarthritis; * Patients with shoulder pain for reasons other than tendinopathy (capsulitis, chronic inflammatory rheumatism, fibromyalgia, amyloidosis); * Patients who have had a subacromial infiltration in the previous 6 months; * Patients with a known allergy to one of the products including their excipients (methyl parahydroxybenzoate, propyl parahydroxybenzoate, benzyl alcohol); * Patients with a known allergy to lidocaine; * Patients with a local or generalised infection, or suspected infection; * Patients with severe coagulation disorders or taking anticoagulants; * Patients with severe and/or uncontrolled hypertension \> 160/100 mmHg; * Patients with unbalanced diabetes (last HbA1c \> 8.5%); * Patients with a history of addiction to psychoactive substances; * Patient participating in another clinical research protocol with an impact on the research objectives; * Patient already randomised in the study; * Patient who is pregnant, parturient, breastfeeding or able to procreate without effective contraception\* in the month prior to inclusion and up to 15 days after infiltration; * Patients under guardianship, curators or deprived of liberty; * Patient under a mandate for future protection activated ; * Patient under family guardianship ; * Patient under court protection ;